Tango Therapeutics (TNGX) Stock Price, News & Analysis

Company Overview

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues. Tango has entered strategic collaborations with major pharmaceutical partners to advance these programs, most notably a multi-asset agreement with GSK to discover and develop DNA damage response inhibitors and a partnership with Merck focused on novel synthetic lethal targets in oncology. These alliances provide access to additional computational tools, screening libraries and global development expertise.

Founded in 2019 as a spin-out from Dana-Farber Cancer Institute and Harvard Medical School, Tango Therapeutics is headquartered in Cambridge, Massachusetts, near one of the world’s leading biopharma clusters. The management team combines scientific founders with broad drug development experience, enabling the company to rapidly translate genetic insights into translational programs. Tango has assembled an advisory board of academic and industry experts to guide target selection and clinical strategy.

With its concentrated focus on synthetic lethality, Tango Therapeutics seeks to address unmet needs in solid tumors and hematologic cancers driven by specific genetic lesions. The company is advancing its pipeline through IND-enabling studies and early clinical trials, aiming to validate its approach of pairing genomic profiling with highly selective therapies. Tango’s platform is designed to uncover novel treatment modalities that could extend the benefits of precision oncology to patient populations beyond those served by current standard-of-care agents.

Key Stats

• Today's Range: $31.09 to $33.53
• 50-Day Range: $19.65 to $32.90
• 52-Week Range: $4.80 to $34.39
• Volume: 4.76 million shs
• Average Volume: 6.43 million shs
• Market Capitalization: $4.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.50
• Consensus Rating: Moderate Buy

Tango Therapeutics Stock Analysis - MarketRank™

Tango Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 351st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tango Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 12 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Tango Therapeutics has a consensus price target of $41.50, representing about 32.8% upside from its current price of $31.26.

Amount of Analyst Coverage

Tango Therapeutics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.28) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tango Therapeutics is -37.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tango Therapeutics is -37.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tango Therapeutics has a P/B Ratio of 12.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.17% of the float of Tango Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tango Therapeutics has a short interest ratio ("days to cover") of 5.43.

Change versus previous month

Short interest in Tango Therapeutics has recently increased by 1.65%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tango Therapeutics does not currently pay a dividend.

Dividend Growth

Tango Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.43

News Sentiment

Tango Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Tango Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 10 people have searched for TNGX on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.

MarketBeat Follows

4 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,724,600.00 in company stock.

Percentage Held by Insiders

6.50% of the stock of Tango Therapeutics is held by insiders.

Percentage Held by Institutions

78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/30/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNGX
• CIK: 1819133
• Web: www.tangotx.com
• Phone: 857-320-4900
• Fax: N/A
• Employees: 90
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Tango Therapeutics: $41.50
• High Price Target: $69.00
• Low Price Target: $14.00
• Potential Upside/Downside: +32.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$101.59 million
• Net Margins: -151.15%
• Pretax Margin: -188.20%
• Return on Equity: -41.54%
• Return on Assets: -33.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.38
• Quick Ratio: 27.38

Sales & Book Value

• Annual Sales: $62.38 million
• Price / Sales: 72.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.57 per share
• Price / Book: 12.16

Miscellaneous

• Outstanding Shares: 144,650,000
• Free Float: 135,246,000
• Market Cap: $4.52 billion
• Optionable: Optionable
• Beta: 1.19